Media

2022-03-19
On March 19, 2022, Mr. Yusuf Timol, Minister Counsellor (Economy) of the South African Embassy BEIJING visited WestVac BioPharma Co., Ltd (WestVac Biopharma), and had a discussion and exchange with the management team of WestVac Biopharma.
Read More
2022-01-10
January 6th to 8th, 2022, Yuan Yuan, head of commerce and business development, GAO Guang, senior technical officer, and DONG Haiyan, senior project officer of Shanghai Representative Office, PATH, visited WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma"), carried out a three-day investigation and training work, and the WestVac Biopharma team accompanied the investigation and held discussion exchange.
Read More
2022-01-06
Recently, the progress of the second generation COVID-19 vaccine of WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma") has attracted international media attention, and has been reported by The Associated Press, Asahi Shinbun, Fox News, Agencia EFE and other overseas authoritative media, causing widespread concern in the global society. In just a few days, more than 600 reports were published.
Read More

About Us

WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac BioPharma") is an innovative biopharmaceutical enterprise integrating vaccine R&D, production and sales. The company’s registered capital is 1.242 billion yuan. With the continuous investment and support of many powerful shareholders -- CICC Capital, Haier Biomedical, Shanghai Pharma, Sichuan Development Holding, China Taiping and so on, WestVac BioPharma has been successfully selected into the list of unicorn companies in 2021.

In terms of production, quality, operations management, etc., WestVac Biopharma has introduced advanced talents from well-known domestic and international vaccine companies, established a complete production and quality management system, has more than 300 employees to ensure large scale production of vaccines can proceed smoothly.

Currently, WestVac Biopharma has a mature insect cell expression platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, tumor vaccine and immunotherapy platform, with more than 30 pipelines including COVID-19 vaccine, multivalent influenza vaccine, herpes virus vaccine, acne vaccine, tumor immunity preparations.

Phase III clinical trials of the first generation Recombinant COVID-19 Vaccine (Sf9 cells)-Coviccine, a second-generation recombinant protein COVID-19 vaccine, have been conducted globally in multiple countries, with nearly 40,000 subjects enrolled and vaccinated, and completed clinical trials in Japan for marketing purposes. It is the first Chinese COVID-19 vaccine that entered clinical trials in a developed country. Study results show that the vaccine has good safety and immunogenicity, and can obviously induce neutralizing antibodies against COVID-19 virus prototype strain and variant strains, which fully embodies the advantages and characteristics of recombinant protein vaccine technology route.

Meanwhile, the second generation Recombinant Variant COVID-19 Vaccine (Sf9 cells) developed by WestVac BioPharma with a high titer neutralizing antibody has achieved significant progresses against COVID-19 mutant strains including Omicron and Delta. The vaccine belongs to the latest fifth generation vaccine technology (fully synthetic vaccine), targeting the S-RBD protein of the COVID-19 mutant strain, the subunit vaccine antigen is precisely designed based on the structure, which can self-assemble into stable protein particles. The large-scale production of vaccines adopts internationally advanced insect cell production technology and combined with oil-in-water emulsion adjuvant WGa01(MF59-like adjuvant) that induces a stronger immune response. It is one of the first COVID-19 vaccines announced internationally that has high titers of neutralizing antibodies against the Omicron mutant strain. The application materials have been submitted to the National Medical Products Administration in August, 2021, and it is expected to officially enter clinical trials in the middle of 2022.

In addition, WestVac BioPharma is also developing a nasal spray version of COVID-19 vaccine, new oral anti-COVID-19 drug, and mRNA COVID-19 vaccine. The current research results show that the three products have good in vivo safety and activity.

WestVac Biopharma has built a production base with an annual production capacity of 1 billion doses in Chengdu Tianfu International Bio-town, has completed the construction and verification of GMP production workshop, and obtained the "Drug Manufacturing License". Three separate product pipelines can be used to produce a variety of recombinant protein vaccines expressed by insect cells, including COVID-19 vaccine, influenza vaccine, herpes vaccine, etc. In addition, Guangzhou production base with an annual capacity of 1 billion doses is also under construction. WestVac Biopharma has also established a good communication with many international organizations such as the World Health Organization (WHO), Gates Foundation, PATH, The Coalition for Epidemic Preparedness Innovations (CEPI) and so on.

In the future, WestVac Biopharma will continue to persist in the corporate philosophy of "We Initiate Science & Technology Value, Always for Caring". Bring innovative vaccines and immunotherapies from China to the world for the benefit of mankind.

Read More

Product R&D

WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac BioPharma") has a mature insect cell expression platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, tumor vaccine and immunotherapy platform, with more than 30 pipelines including COVID-19 vaccine, multivalent influenza vaccine, herpes virus vaccine, acne vaccine, tumor immunity preparations.

After the outbreak of COVID-19 in early 2020, with the strong support of governments at all levels, Sichuan University West China Medical Center and WestVac BioPharma took the initiative to participate in the scientific and technological action against COVID-19, and made breakthroughs through more than one year\'s efforts. Affiliated to Sichuan University, West China Medical Center is the largest national medical center in western China. Its State Key Laboratory of Biotherapy is the only laboratory of its kind with the mandate of "Treating Critical Human Disease with Biotechnology". There are over 150 experts with multi-disciplinary background, including 13 Chang Jiang Scholars/Young Chang Jiang Scholars and 18 winners of the National Science Fund for Distinguished Young Scholars.

Under the joint Prevention and Control Mechanism of The State Council, Sichuan University and WestVac BioPharma jointly undertook the research and development of Recombinant COVID-19 Vaccine (Sf9 cells), a national key scientific research project. Led by Professor WEI Yuquan, Academician of the Chinese Academy of Sciences, Director of the State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, and Chairman of WestVac BioPharma, and his team of scientists, the project belongs to one of the five state-funded COVID-19 vaccine development technology routes.

On July 29, 2020, WestVac Biopharma R&D team published the first COVID-19 vaccine research paper in the journal Nature. They used an innovative recombinant protein technology route for R&D. It\'s China\'s first recombinant subunit COVID-19 vaccines expressed in insect cells. S protein of SARS-CoV-2 was prepared by introducing SARS-CoV-2 genes into insect cells which can induce human body to produce antibodies to block viral infection. Large production of protein has been achieved.

The Phase I and II clinical trials of Coviccine have been completed in June 2021. Currently, Phase III clinical trials are progressing smoothly in Mexico, the Philippines, Indonesia, Kenya and other countries, and nearly 40,000 subjects have been enrolled and vaccinated, and required clinical trials have been completed in Japan. It is the first Chinese COVID-19 vaccine that entered clinical trials in a developed country. Primary research results show that the vaccine has good safety and immunogenicity, and can evidently induce neutralizing antibodies against the prototype and variant strains of SARS-CoV-2, which fully reflects the advantages and characteristics of the recombinant protein vaccine technology. Furthermore, using Coviccine as the third dose in sequential vaccination after using existing COVID-19 vaccines on the market significantly increased neutralizing antibody titers against multiple variant strains such as Omicron, Delta and other variants.

WestVac Biopharma is also accelerating the development of the second-generation recombinant COVID-19 vaccine (Sf9 cells) in response to the continuous emergence of mutated strains such as Delta and Omicron strains. The vaccine belongs to the latest fifth generation vaccine technology (fully synthetic vaccine), targeting the S-RBD protein of the COVID-19 mutant strain, the subunit vaccine antigen is precisely designed based on the structure, which can self-assemble into stable nanoparticles. The large-scale production of the vaccine uses internationally advanced insect cell production technology and is combined with oil-in-water emulsion adjuvant (MF59-like adjuvant) that can induce a stronger immune response. The vaccine can induce the production of high titers of neutralizing antibodies upon immunizing animals such as mice or monkeys. The neutralizing antibodies against the Omicron variant strain can reach a level of ten thousands (it means that the blood is diluted 10,000 times and still has the ability to block the virus from infecting cells). It was previously discovered that the vaccine has a level of ten thousands neutralizing antibodies that completely inhibits Brazilian strains, South African strains, Delta strains and other mutant strains of Euvirus, suggesting that the vaccine is a universal COVID-19 against multiple mutant strains. It is also the first COVID-19 vaccine announced internationally that has high titers of neutralizing antibodies against the Omicron mutant strain. At present, the application materials have been submitted to the National Medical Products Administration in August, 2021, and it is expected to officially enter clinical trials in the middle of 2022.

In order to improve the safety and accessibility of the vaccine, WestVac Biopharma has also developed a nasal spray vaccine against COVID-19 variants, improving efficiency of protection by inducing nasal mucosal immunity. On the basis of the extensive research, the nasal spray type was selected to induce strong immune response. After two immunizations, rabbits can be induced to produce more than one hundred thousand binding antibodies, and there are obvious neutralizing antibodies. Additionally, the company is also in the process of developing the new oral anti-COVID-19 drug and the mRNA COVID-19 vaccine, both of which have been shown to have good in vivo safety and activity.

Read More

Commercialization

WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac BioPharma") is an innovative biopharmaceutical enterprise integrating vaccine R&D, production and sales. The company’s registered capital is 1.242 billion yuan. The company is located in Chengdu Tianfu International Bio-town. WestVac Biopharma has a mature insect cell expressed recombinant protein platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, tumor vaccine and immunotherapy platform. The company is committed to the development and production of a variety of innovative vaccines and immunotherapy products.

WestVac Biopharma has built a production base with an annual production capacity of 1 billion doses in Chengdu Tianfu International Bio-town. The layout of production line is optimized, the production process is scientific and safe, and the production equipment is basically made in China. The company has completed the construction and verification of GMP production workshop, and obtained the "Drug Manufacturing License".Three separate product pipelines can be used to produce a variety of recombinant protein vaccines expressed by insect cells, including COVID-19 vaccine, influenza vaccine, herpes vaccine, etc. In addition, Guangzhou production base with an annual capacity of 1 billion doses is also under construction.

In terms of production, quality, operations management, etc., WestVac Biopharma has introduced advanced talents from well-known domestic and international vaccine companies, established a complete production and quality management system, has more than 300 employees to ensure that large scale production of vaccines can proceed smoothly.

WestVac Biopharma has also established a good communication with many international organizations such as the World Health Organization (WHO), Gates Foundation, PATH, The Coalition for Epidemic Preparedness Innovations (CEPI) and so on. The company has submitted an application for emergency use of COVID-19 vaccine (EUL) to the World Health Organization (WHO), hoping to contribute to global COVID-19 prevention and control.

Read More